Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

The Lancet Oncology

Volumn 11, Issue 1, 2010, Pages 48-54

  Zhu, Andrew X ^a   Meyerhardt, Jeffrey A ^a   Blaszkowsky, Lawrence S ^a   Kambadakone, Avinash R ^b   Muzikansky, Alona ^b   Zheng, Hui ^b   Clark, Jeffrey W ^a   Abrams, Thomas A ^a   Chan, Jennifer A ^a   Enzinger, Peter C ^a   Bhargava, Pankaj ^a   Kwak, Eunice L ^a   Allen, Jill N ^a   Jain, Sanjay R ^a   Stuart, Keith ^c   Horgan, Kerry ^d   Sheehan, Susan ^d   Fuchs, Charles S ^a   Ryan, David P ^a   Sahani, Dushyant V ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; OXALIPLATIN;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT CANCER; BLEEDING; BONE MARROW SUPPRESSION; CANCER CONTROL; CANCER SUSCEPTIBILITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 73249128451     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70333-X     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 (2004) 115-125
3. Vauthey J.N., and Blumgart L.H. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 14 (1994) 109-114
4. Hezel A.F., and Zhu A.X. Systemic therapy for biliary tract cancers. Oncologist 13 (2008) 415-423
5. Cho J.Y., Paik Y.H., Chang Y.S., et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104 (2005) 2753-2758
6. Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23 (2005) 2332-2338
7. Riechelmann R.P., Townsley C.A., Chin S.N., et al. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110 (2007) 307-312
8. André T., Reyes-Vidal J.M., Fartoux L., et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 99 (2008) 862-867
9. Harder J., Riecken B., Kummer O., et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 95 (2006) 848-852
10. Verderame F., Russo A., Di Leo R., et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol 17 suppl 7 (2006) 68-72
11. André T., Tournigand C., Rosmorduc O., et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15 (2004) 1339-1343
12. Valle J.W., Wasan H.S., Palmer D.D., et al. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). Proc Am Soc Clin Oncol 27 15 suppl (2009) abstr 4503.
13. Hida Y., Morita T., Fujita M., et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res 19 (1999) 2257-2260
14. Giatromanolaki A., Koukourakis M.I., Simopoulos C., et al. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol 29 (2003) 879-883
15. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
16. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
17. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25 (2007) 1539-1544
18. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
19. Cloughesy T., Prados M., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan prolongs progression-free survival and increases objective response in recurrent glioblastoma. Proc Am Soc Clin Oncol 26 15 suppl (2008) abstr 2010.
20. Jain R.K. Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
21. Therasse P., Eisenhauer E.A., and Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42 (2006) 1031-1039
22. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 35 (1999) 1773-1782
23. Eckel F., and Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96 (2007) 896-902
24. Taïeb J., Bonyhay L., Golli L., et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98 (2003) 2664-2670
25. Thongprasert S., Napapan S., and Charoentum C. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16 (2005) 279-281
26. Park B.K., Kim Y.J., Park J.Y., et al. Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol 21 (2006) 999-1003
27. Kim S.T., Park J.O., Lee J., et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106 (2006) 1339-1346
28. Meyerhardt J.A., Zhu A.X., Stuart K., et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 53 (2008) 564-570
29. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 1898-1903
30. Paule B., Herelle M.O., Rage E., et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72 (2007) 105-110
31. Gruenberger B., Schueller J., Tamandl D., et al. K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center phase II study. Proc Am Soc Clin Oncol 27 15 suppl (2009) abstr 4586.
32. Malka D., Trarbach T., Fartoux L., et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial. Proc Am Soc Clin Oncol 27 15 suppl (2009) abstr 4520.
33. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24 (2006) 3069-3074
34. Safran H., Miner T., Resnick M., et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol 31 (2008) 140-144
35. Dealis C., Bertolini F., Malavasi N., et al. A phase II trial of sorafenib (SOR) in patients (pts) with advanced cholangiocarcinoma (CC). Proc Am Soc Clin Oncol 26 15 suppl (2008) abstr 4590.
36. Ramanathan R.K., Belani C.P., Singh D.A., et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64 (2009) 777-783